IBT reported a larger operating loss in H1 2024 as it completed its pivotal Phase 3 trial for IBP-9414, with results expected in Q3 2024. Cash reserves remain strong, and regulatory and commercial preparations are underway.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.